Nektar Therapeutics Cash and Cash Equivalents, Period Increase (Decrease)
Nektar Therapeutics (NKTR) reported Cash and Cash Equivalents, Period Increase (Decrease) of $906.36 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-08-09
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $876.32M.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $30.04M.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$33.20M.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $21.82M, a 186.36% increase year-over-year.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$54.88M, a 1448.35% decline from fiscal 2016.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for fiscal 2016 was $4.07M, a 90.58% decline from fiscal 2015.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for fiscal 2015 was $43.20M.
- Nektar Therapeutics cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$26.70M, a 295.91% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $876.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $906.36M 10-Q · filed 2018-08-09 | $873.16M derived: sum of 3 quarters · filed 2018-08-09 | $894.98M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $30.04M 10-Q · filed 2018-05-10 | -$3.16M derived: sum of 2 quarters · filed 2018-05-10 | $18.66M derived: sum of 3 quarters · filed 2018-05-10 | $11.32M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-12-31 | -$33.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$11.39M derived: sum of 2 quarters · filed 2018-03-01 | -$18.72M derived: sum of 3 quarters · filed 2018-08-09 | -$54.88M 10-K · filed 2018-03-01 |
| 2017-09-30 | $21.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $14.49M derived: sum of 2 quarters · filed 2018-08-09 | -$21.67M 10-Q · filed 2017-11-08 | -$25.33M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | -$7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$43.49M 10-Q · filed 2018-08-09 | -$47.15M derived: sum of 3 quarters · filed 2018-08-09 | -$39.53M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$36.16M 10-Q · filed 2018-05-10 | -$39.81M derived: sum of 2 quarters · filed 2018-05-10 | -$32.20M derived: sum of 3 quarters · filed 2018-05-10 | -$49.07M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $3.96M derived: sum of 2 quarters · filed 2018-03-01 | -$12.91M derived: sum of 3 quarters · filed 2018-03-01 | $4.07M 10-K · filed 2018-03-01 |
| 2016-09-30 | $7.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$9.25M derived: sum of 2 quarters · filed 2017-11-08 | $7.72M 10-Q · filed 2017-11-08 | $44.48M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$16.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $106.00K 10-Q · filed 2017-08-09 | $36.86M derived: sum of 3 quarters · filed 2018-03-01 | $34.80M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $16.98M 10-Q · filed 2017-05-10 | $53.73M derived: sum of 2 quarters · filed 2018-03-01 | $51.67M derived: sum of 3 quarters · filed 2018-03-01 | -$56.90M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $36.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $34.70M derived: sum of 2 quarters · filed 2018-03-01 | -$73.88M derived: sum of 3 quarters · filed 2018-03-01 | $43.20M 10-K · filed 2018-03-01 |
| 2015-09-30 | -$2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$110.63M derived: sum of 2 quarters · filed 2016-11-04 | $6.45M 10-Q · filed 2016-11-04 | -$13.19M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$108.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $8.51M 10-Q · filed 2016-08-04 | -$11.13M derived: sum of 3 quarters · filed 2017-03-01 | -$9.82M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $117.09M 10-Q · filed 2016-05-04 | $97.44M derived: sum of 2 quarters · filed 2017-03-01 | $98.75M derived: sum of 3 quarters · filed 2017-03-01 | $97.01M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$19.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$18.33M derived: sum of 2 quarters · filed 2017-03-01 | -$20.08M derived: sum of 3 quarters · filed 2017-03-01 | -$26.70M 10-K · filed 2017-03-01 |
| 2014-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$435.00K derived: sum of 2 quarters · filed 2015-11-06 | -$7.06M 10-Q · filed 2015-11-06 | -$33.40M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$8.37M 10-Q · filed 2015-08-06 | -$34.71M derived: sum of 3 quarters · filed 2016-02-29 | -$10.73M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$6.62M 10-Q · filed 2015-05-01 | -$32.97M derived: sum of 2 quarters · filed 2016-02-29 | -$8.99M derived: sum of 3 quarters · filed 2016-02-29 | $3.91M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$26.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$2.37M derived: sum of 2 quarters · filed 2016-02-29 | $10.54M derived: sum of 3 quarters · filed 2016-02-29 | $13.63M 10-K · filed 2016-02-29 |
| 2013-09-30 | $23.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $36.88M derived: sum of 2 quarters · filed 2014-11-07 | $39.97M 10-Q · filed 2014-11-07 | $55.07M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $15.99M 10-Q · filed 2014-08-01 | $31.09M derived: sum of 3 quarters · filed 2015-02-26 | -$94.72M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $3.09M 10-Q · filed 2014-05-08 | $18.19M derived: sum of 2 quarters · filed 2015-02-26 | -$107.62M derived: sum of 3 quarters · filed 2015-02-26 | -$119.95M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $15.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$110.72M derived: sum of 2 quarters · filed 2015-02-26 | -$123.05M derived: sum of 3 quarters · filed 2015-02-26 | $10.13M 10-K · filed 2015-02-26 |
| 2012-09-30 | -$125.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$138.15M derived: sum of 2 quarters · filed 2013-11-07 | -$4.97M 10-Q · filed 2013-11-07 | -$32.67M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$12.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $120.84M 10-Q · filed 2013-08-09 | $93.15M derived: sum of 3 quarters · filed 2014-02-27 | $124.53M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $133.17M 10-Q · filed 2013-05-09 | $105.48M derived: sum of 2 quarters · filed 2014-02-27 | $136.86M derived: sum of 3 quarters · filed 2014-02-27 | $126.00M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$27.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $3.69M derived: sum of 2 quarters · filed 2014-02-27 | -$7.17M derived: sum of 3 quarters · filed 2014-02-27 | -$2.44M 10-K · filed 2014-02-27 |
| 2011-09-30 | $31.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $20.52M derived: sum of 2 quarters · filed 2012-11-09 | $25.25M 10-Q · filed 2012-11-09 | $30.10M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$10.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$6.13M 10-Q · filed 2012-08-09 | -$1.28M derived: sum of 3 quarters · filed 2013-03-01 | -$11.62M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $4.73M 10-Q · filed 2012-05-04 | $9.58M derived: sum of 2 quarters · filed 2013-03-01 | -$759.00K derived: sum of 3 quarters · filed 2013-03-01 | $1.91M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$5.49M derived: sum of 2 quarters · filed 2013-03-01 | -$2.82M derived: sum of 3 quarters · filed 2013-03-01 | -$31.84M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$10.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$7.67M derived: sum of 2 quarters · filed 2011-11-04 | -$36.69M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | -$26.35M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | -$29.02M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | -$105.99M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |